Metagenomi Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
MGX$0.70-3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net loss | $(23,059) | $(25,039) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Stock-based compensation expense | 2,552 | 2,928 |
| Depreciation | 1,275 | 1,358 |
| Non-cash lease expense | 1,335 | 1,273 |
| Accretion of discounts on available-for-sale marketable securities | (360) | (1,007) |
| Amortization of non-cash collaboration revenue | — | (77) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 305 | 245 |
| Prepaid expenses and other assets | 230 | 2,237 |
| Accounts payable | 795 | 2,210 |
| Deferred revenue | (748) | (3,049) |
| Accrued expenses and other current liabilities | (2,029) | (2,648) |
| Operating lease liabilities | (1,471) | (1,371) |
| Other non-current liabilities | — | 98 |
| Net cash used in operating activities | (21,175) | (22,842) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (25) | (288) |
| Purchases of available-for-sale marketable securities | (36,748) | (22,287) |
| Maturities of available-for-sale marketable securities | 40,759 | 47,303 |
| Net cash provided by investing activities | 3,986 | 24,728 |
| Cash flows from financing activities | ||
| Payment of deferred financing costs | (27) | (77) |
| Net cash used in financing activities | (27) | (77) |
| Net increase (decrease) in cash, cash equivalents and restricted cash | (17,216) | 1,809 |
| Cash, cash equivalents and restricted cash at beginning of period | 46,915 | 32,634 |
| Cash, cash equivalents and restricted cash at end of period | $29,699 | $34,443 |
| Supplemental disclosure of non-cash information | ||
| Purchases of property and equipment included in accounts payable, accrued expenses and other current liabilities | $124 | $23 |
| Deferred finance issuance costs included in accounts payable, accrued expenses and other current liabilities | $2 | $422 |
| Reconciliation of cash, cash equivalents and restricted cash | ||
| Cash and cash equivalents | $25,306 | $29,195 |
| Restricted cash | 4,393 | 5,248 |
| Cash, cash equivalents and restricted cash at end of period | $29,699 | $34,443 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.